As therapeutics increase in complexity and global demand continues to rise, drug sponsors must adapt their pharmacovigilance (PV), Medical Information (MI), and lifecycle management (LCM) approaches to accommodate new challenges. Many drug sponsors are considering how technologies like artificial intelligence (AI), machine learning (ML), and natural language processing (NLP) can improve existing PV, MI, and LCM workflows. To seamlessly integrate these technologies, sponsors are also assessing the impact of partnering with experienced technology providers. To prepare your teams for 2025, consider how AI and other innovations are helping drug sponsors manage growing workloads.
It is important to stay diligent and adaptive to technological trends to ensure continued market success and proper lifecycle management for your product. Throughout 2024, AI was implemented across LCM, MI, and PV workflows to accommodate changing volumes and needs. Now, experts are projecting the following AI trends in 2025:
Drug companies must build a broad toolkit, emphasize cross-team collaboration, and enlist the help of seasoned experts wherever possible. Some recommendations include:
In a recent webinar hosted by IQVIA, experts across key functional areas spoke about the trends they are seeing across this space, including increased adoption of AI across MI and PV, evolving partnerships with streamlined service providers, and growing regulatory acknowledgement of AI. Looking to explore what trends are ahead in 2025? Watch the full webinar or read the white paper, 2025 Safety and Regulatory Compliance Trends and Predictions for Pharma and Biotech.
Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.
.svg){kind=icon}
